Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fritz Offner

Showing results (81-90 of 126) with videos related to

Pageof 13
Sort By:
The Lancet. Oncology|July 5, 2011
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trialBertrand Coiffier, Evgenii A Osmanov, Xiaonan Hong, et al.
Haematologica|October 15, 2020
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1Eugen Tausch, Philipp Beck, Richard F Schlenk, et al.
The New England Journal of Medicine|December 12, 2022
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell LymphomaMichael J Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Annals of Medicine|June 18, 2013
Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physiciansJo Caers, Marie-Christiane Vekemans, Greet Bries, et al.
Lancet (London, England)|April 18, 2015
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trialPeter Hillmen, Tadeusz Robak, Ann Janssens, et al.
Haematologica|June 9, 2018
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Paul M Barr, Tadeusz Robak, Carolyn Owen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2021
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 StudyMarie José Kersten, Karima Amaador, Monique C Minnema, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2018
The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter StudyBasile Stamatopoulos, Thomas Smith, Emerence Crompot, et al.
The Lancet. Haematology|March 19, 2018
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trialJennifer R Brown, Mehdi Hamadani, John Hayslip, et al.
Pageof 13

Showing results (81-90 of 126) with videos related to

Sort By:
Pageof 13
The Lancet. Oncology|July 5, 2011
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trialBertrand Coiffier, Evgenii A Osmanov, Xiaonan Hong, et al.
Haematologica|October 15, 2020
Prognostic and predictive role of gene mutations in chronic lymphocytic leukemia: results from the pivotal phase III study COMPLEMENT1Eugen Tausch, Philipp Beck, Richard F Schlenk, et al.
The New England Journal of Medicine|December 12, 2022
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell LymphomaMichael J Dickinson, Carmelo Carlo-Stella, Franck Morschhauser, et al.
Eclinicalmedicine|January 9, 2023
The iR<sup>2</sup> regimen (ibrutinib plus lenalidomide and rituximab) for relapsed/refractory DLBCL: A multicentre, non-randomised, open-label phase 2 studyRadhakrishnan Ramchandren, Peter Johnson, Nilanjan Ghosh, et al.
Annals of Medicine|June 18, 2013
Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physiciansJo Caers, Marie-Christiane Vekemans, Greet Bries, et al.
Lancet (London, England)|April 18, 2015
Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trialPeter Hillmen, Tadeusz Robak, Ann Janssens, et al.
Haematologica|June 9, 2018
Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2Paul M Barr, Tadeusz Robak, Carolyn Owen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 13, 2021
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 StudyMarie José Kersten, Karima Amaador, Monique C Minnema, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2018
The Light Chain IgLV3-21 Defines a New Poor Prognostic Subgroup in Chronic Lymphocytic Leukemia: Results of a Multicenter StudyBasile Stamatopoulos, Thomas Smith, Emerence Crompot, et al.
The Lancet. Haematology|March 19, 2018
Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trialJennifer R Brown, Mehdi Hamadani, John Hayslip, et al.
Pageof 13